Introduction: Moderately-effective therapies (MET) have been the main treatment in pediatric- onset multiple sclerosis (POMS) for years. Despite the expanding use of highly-effective therapies (HET), therapeutic guidelines for POMS are missing.Objectives/Aims: To assess the real-world effectiveness of HET as immediate treatment compared with...
-
October 11, 2023 (v1)Conference paperUploaded on: October 12, 2024
-
October 2024 (v1)Journal article
Background and objectives: Although rituximab failed to demonstrate a significant effect on disability progression in primary progressive multiple sclerosis (PPMS), ocrelizumab succeeded. Our main objective was to analyze confirmed disability progression (CDP) in a cohort of patients with PPMS treated with anti-CD20 therapies compared with a...
Uploaded on: October 4, 2024 -
October 1, 2021 (v1)Journal article
IMPORTANCE: Younger age, oligoclonal bands, and infratentorial and spinal cord lesions are factors associated with an increased 10-year risk of clinical conversion from radiologically isolated syndrome (RIS) to multiple sclerosis (MS). Whether disease-modifying therapy is beneficial for individuals with RIS is currently unknown. OBJECTIVES: To...
Uploaded on: December 3, 2022